The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

Mealing, Stuart; Barcena, Leticia; Hawkins, Neil; Clark, James; Eaton, Victoria; Hirji, Ishan; Davis, Catherine

doi:10.1186/2162-3619-2-5

Table 1 Description of included studies

From: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

Study	Study characteristics							Assessment of study quality
Study	Study design	Study duration (months)	Interventions	N	Median follow up (months)	Median dose	% lost to follow up	Q1	Q2	Q3	Q4	Q5	Q6
DASISION [13, 29–31]	Multicentre, Randomised, Phase III		Dasatinib 100 mg^a	259	18.0	99 mg	15%	Yes	No	Yes	No	Yes	Yes
DASISION [13, 29–31]	Multicentre, Randomised, Phase III		Imatinib 400 mg^a	260	18.0	400 mg	19%
Baccarani et al. [32]	Prospective, randomised	12	Imatinib 400 mg^a	108	26	400 mg		No	Yes	No	Yes	Yes	No
Baccarani et al. [32]	Prospective, randomised	12	Imatinib 800 mg^a	108	26	720 mg
German CML Study IV [33, 34]	Randomised	36	Imatinib 800 g^a	338	40	646 mg		Yes	No	No	No	No	No
German CML Study IV [33, 34]	Randomised	36	Imatinib 400 g^a	326	40	400 mg
ENESTed [12, 35–37]	Multicentre, Randomised, Phase III	60	Nilotinib 300 mg^b	282	18	592 mg	16%	Yes	No	Yes	No	Yes	Yes
			Nilotinib 400 mg^b	281	18	779 mg	18%
			Imatinib 400 mg^a	283	18	400 mg	21%
S0325 Intergroup [38]	Open Label, Randomised, Phase II	12	Imatinib 400 mg^a	127				Yes	No	No	No	No	No
S0325 Intergroup [38]	Open Label, Randomised, Phase II	12	Dasatinib 100 mg^a	126
ISTAHIT [39]	Multicentre, Randomised, Phase III	24	Imatinib 400 mg^a	114	12.75	400 mg		Yes	No	Yes	No	Yes	Yes
ISTAHIT [39]	Multicentre, Randomised, Phase III	24	Imatinib 800 mg^a	113	12.75	767 mg
Cortes et al. [40]	Multicentre, Randomised, Phase III	12	Imatinib 400 mg^a	157	17		0%	No	No	Yes	No	Yes	Yes
Cortes et al. [40]	Multicentre, Randomised, Phase III	12	Imatinib 400 mg^a	319	17		0.6%
SPIRIT [41]	Prospective, Randomised, Phase III	24	Imatinib 400 mg^a	159	47	400 mg	0%	Yes	No	Yes	No	Yes	Yes
SPIRIT [41]	Prospective, Randomised, Phase III	24	Imatinib 600 mg^a	160	47	590 mg	0%

a) SID; b) BID; Q1) Was the method used to randomize patients described and adequate?; Q2) Was the method used for allocation concealment described and adequate?; Q3) Were the detailed inclusion/exclusion criteria described?; Q4) Was the method used to ensure treatment blinding described and adequate?; Q5) Were the patient baseline characteristics described? Q6) Were all analyses carried out using data from the Intention To Treat (ITT) patient group?

Back to article page

ISSN: 2162-3619

Contact us

Submission enquiries: journalsubmissions@springernature.com

Experimental Hematology & Oncology

Contact us